[{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Summit Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Ridinilazole","moa":"Cell Division","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"10","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel","graph1":"Neurology","graph2":"Approved","graph3":"Eurofarma Laboratorios S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable Suspension","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"12","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Eurofarma Laboratorios S.A","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Cenobamate","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eurofarma Laboratorios S.A","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"12","companyTruncated":"Eurofarma Laboratorios S.A \/ Eurofarma Laboratorios S.A"}]

Find Clinical Drug Pipeline Developments & Deals by Eurofarma Laboratorios S.A

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : Under the terms of agreement, SK Biopharmaceuticals has granted Eurofarma the exclusive rights to develop and commercialize Xcopri (cenobamate) in Latin America. SK Biopharmaceuticals will now be present in four continents: North America, Europe, Asia, a...

Product Name : Xcopri

Product Type : Small molecule

Upfront Cash : $15.0 million

July 14, 2022

Lead Product(s) : Cenobamate

Therapeutic Area : Neurology

Highest Development Status : Approved

Recipient : SK Biopharmaceuticals

Deal Size : $62.0 million

Deal Type : Licensing Agreement

blank

02

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : Under the terms of the agreement, Eurofarma obtains the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia, and Mexico.

Product Name : Exparel

Product Type : Small molecule

Upfront Cash : Undisclosed

June 22, 2021

Lead Product(s) : Bupivacaine

Therapeutic Area : Neurology

Highest Development Status : Approved

Recipient : Pacira BioSciences

Deal Size : Undisclosed

Deal Type : Agreement

blank

03

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : The milestone payment was initiated by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Undisclosed

February 06, 2020

Lead Product(s) : Ridinilazole

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Recipient : Summit Therapeutics

Deal Size : $3.8 million

Deal Type : Collaboration

blank